Stocktoria
Bioventus Inc. BVS
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2021-02-11
Bioventus Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 68.3% | 67.7% | 64.1% | 64.6% | 70.3% |
| Operating margin | 9.5% | -2.7% | -16.0% | -32.7% | 2.8% |
| Net margin | 4.0% | -6.3% | -30.5% | -31.0% | 4.5% |
| FCF margin | 12.7% | 6.6% | 2.0% | -2.9% | 2.2% |
| Return on assets | 3.3% | -5.0% | -19.3% | -11.6% | 1.6% |
| Return on equity | 10.0% | -19.5% | -70.7% | -38.5% | 3.2% |
| Debt / equity | 1.22× | 1.66× | 1.66× | 0.93× | 0.59× |
| Current ratio | 1.70 | 1.31 | 1.53 | 0.90 | 1.45 |
| Revenue growth | -0.9% | 11.9% | 0.0% | 18.8% | 34.2% |
Source: SEC EDGAR filings · CIK 0001665988 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.